A Randomized Non-Comparative Phase II Study of Nivolumab or Nivolumab/BMS-986205 alone or combined with Intravesical BCG in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer | NYU Langone Health

A Randomized Non-Comparative Phase II Study of Nivolumab or Nivolumab/BMS-986205 alone or combined with Intravesical BCG in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non-muscle Invasive Bladder Cancer
Age: Between 18 years - 100 years
Gender: Female

Other Inclusion Criteria:

1. Pathologically confirmed High-Risk, Non-Muscle Invasive Bladder Cancer 2. BCG-Unresponsive (BCG (Bacille Calmette Guerin) treatment is defined as at least 2 courses of BCG)

You may not be eligible for this study if the following are true:

1. Patients with an active, known or suspected autoimmune disease. 2. Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.